SEC Form 4 · accession 0001613377-17-000044
AIM ImmunoTech Inc. · AIM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas K. Equels
Officer — CEO / President
Period of report
Aug 31, 2017
Accepted (ET)
Sep 1, 2017 · 2:15 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000946644
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Options to buy Common StockF1 | $0.36 | Aug 31, 2017 | A | 24,463 | A | Aug 31, 2017 | Aug 31, 2027 | Common Stock | 24,463 | 24,463 | D |
Explanation of responses
- F1This option is being issued in exchange for a voluntary 20% deduction in salary.